Kumar Mukesh, Sharma Yogeshwar, Bandi Sriram, Gupta Sanjeev
Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
J Med Virol. 2015 Jul;87(7):1168-83. doi: 10.1002/jmv.24145. Epub 2015 Feb 17.
Superior cell culture models for hepatitis B virus (HBV) will help advance insights into host-virus interactions. To identify mechanisms regulating HBV replication, this study used cultured human HepG2 cells and adult or fetal hepatocytes transduced with adenoviral vector to express HBV upstream of green fluorescent protein. The vector efficiently transduced all cell types. In HepG2 cells, replicative viral intermediates, nucleocapsid-associated HBcAg, and HBsAg were expressed. However, in fetal or adult hepatocytes, pregenomic HBV RNA and viral RNAs were expressed, but nucleocapsid-associated HBcAg in cells or HBsAg in culture medium were absent, indicating interruptions in viral replication due to possible microRNA-related interference. MicroRNA profiling demonstrated that a large number of microRNAs with antiviral potential were differentially expressed in hepatocytes after culture. In transfection assays using HepG2 cells, candidate antiviral microRNAs, e.g., hsa-miR-24 or hsa-miR-638 decreased the levels of HBV transcripts or HBV gene products. Since candidate microRNAs could have targeted interferon response genes as an alternative explanation interferon signaling was examined. However, HBV replication in cultured hepatocytes was not restored despite successful inhibition of JAK1/2-STAT signaling by the inhibitor, ruxolitinib. Therefore, HBV was unable to complete replication in cultured hepatocytes due to expression of multiple antiviral microRNAs. This mechanism should help understand restrictions in HBV replication for developing HBV models in cultured cells while providing frameworks for pathophysiological studies of HBV replication in subsets of hepatocytes or stem/progenitor cells during hepatitis.
用于乙型肝炎病毒(HBV)的优质细胞培养模型将有助于深入了解宿主与病毒的相互作用。为了确定调节HBV复制的机制,本研究使用培养的人HepG2细胞以及用腺病毒载体转导以在绿色荧光蛋白上游表达HBV的成人或胎儿肝细胞。该载体有效地转导了所有细胞类型。在HepG2细胞中,表达了复制性病毒中间体、核衣壳相关的HBcAg和HBsAg。然而,在胎儿或成人肝细胞中,表达了前基因组HBV RNA和病毒RNA,但细胞中不存在核衣壳相关的HBcAg,培养基中也不存在HBsAg,这表明由于可能的微小RNA相关干扰,病毒复制受到了中断。微小RNA分析表明,大量具有抗病毒潜力的微小RNA在培养后的肝细胞中差异表达。在使用HepG2细胞的转染试验中,候选抗病毒微小RNA,如hsa-miR-24或hsa-miR-638,降低了HBV转录本或HBV基因产物的水平。由于候选微小RNA可能靶向干扰素反应基因作为另一种解释,因此对干扰素信号进行了检测。然而,尽管抑制剂鲁索替尼成功抑制了JAK1/2-STAT信号,但培养的肝细胞中的HBV复制并未恢复。因此,由于多种抗病毒微小RNA的表达,HBV无法在培养的肝细胞中完成复制。这一机制应有助于理解HBV复制的限制,以便在培养细胞中建立HBV模型,同时为肝炎期间肝细胞亚群或肝干细胞/祖细胞中HBV复制的病理生理学研究提供框架。